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ABSTRACT
  Chronic hepatotropic viruses commonly evade the antiviral defence systems of the body and cause a
long - lasting persistent infection. The prolonged nature of the infection ensures that every infected person
has ample opportunity to transmit the virus to others, allowing many millions of people world-wide to     become
infected. Three viruses commonly cause chronic hepatitis B virus, hepatitis C virus and hepatitis Delta virus.
Virus specific CD8 T cells of the host, represent the main effector cells against viral infection. Where as
the antiviral cytokines have a major role in the control of viral replication (non-cytolytic inhibition).
To cause persistent infection, a virus must avoid the host defences and that hepatotropic viruses have
developed elaborate strategies to achieve this. In the case of hepatitis B virus, two proteins are involved in
the inhibition of the host defences; those are the core protein that has been shown to inhibit the production
of interferon and the polymerase protein has been shown to inhibit its effect. Where as in the case of hepatitis
C virus, the NS5A and E2 protein reduce the effect of interferon by inhibiting the antiviral kinase.
In order to survive and persistent in the liver, the hepatotropic viruses must be able to avoid both arms of
the immune system, either by mutation of viral proteins or by preventing activation of the immune system.
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INTRODUCTION
Viral hepatitis is a systemic disease primarily
involving the liver and necroinflammatory is basically
responsible for the majority of its clinical and laboratory
features.1 In viral hepatitis, depending on its etiology, there
is a variable incidence of clinically significant hepatic
and extrahepatic manifestations, complications and
progression to chronicity.
Chronic hepatitis is defined as a chronic
inflammatory reaction of the liver of more than six
months duration, as demonstrated by persistently
abnormal serum aminotransaminase levels and
characteristic histologic findings.2 The ultimate goal
therapy to chronic hepatitis is to heal hepatic
inflammation and necrosis, thereby halting progression
to cirrhosis and hepatocellular carcinoma.3
ETIOLOGY
Three viruses commonly cause chronic viral
hepatitis: hepatitis B virus (HBV), hepatitis delta virus
(HDV) and hepatitis C virus (HCV).Virulogically these
three pathogens are remarkably different (HBV is a DNA
virus, while HDV and HCV are RNA viruses), but all
have developed mechanisms that allow persistent
infection and overall they infect over 500 millions people
world-wide.4 Hepatitis B virus (HBV) is a non-
cytopathic, hepatotrophic DNA virus that cause acute
and chronic necroinflammatory liver disease.
The vast majority of adults acutely infected, recover
from the disease, controlling virus replication and
developing a long lasting immunity, only in about 5%
progress to chronic state. In contrast, neonatal
infections are rarely cleared and most (± 90%) of these
children become chronically infected.5
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Chronic hepatitis B is characterized by a state of
HBV–specific T cell hyporenponsiveness. HBV-specific
cytotoxic T cells mediate protection but can also be the
principle effectors of liver damage. An efficient
HBV-specific CD8 response can promote viral control
without persistent liver pathology, whereas an inadequate
CTL response, may contribute to liver pathology not only
directly, but also via the recruitment of non-antigen-
specific T cells into the infected liver.5
Hepatitis D virus is a unique hepatitis RNA virus.
It is replication defective, though, in that it is incapable
of making its own envelope protein, rather its envelope
consists of the hepatitis B surface antigen (HbsAg),
therefore envelope production require HBV and HVD
transmission and entry into hepatocyte, require HBV
though super infection or co-infection.6
Acute co-infection with HBV, the infection usually in
80% to 95% of cases, with elimination of HBV though
humoral and cellular resolves immune mechanism.
In contrast, super infection may result in chronic HDV-
HBV in more than 70% to 80% of cases. Similar to
acute co-infection, acute HDV super infection may
result in fulminate hepatitis in 2% to 20% of cases.6
Chronic HDV does progress to cirrhosis frequently
and the development of cirrhosis is also more rapid than
chronic HBV or chronic HCV and there is
predominance of co infected patients with cirrhosis who
are young. Slowly progressive mild disease is more
common in endemic areas. On the other hand, HDV
disease appear to be more severe in non-endemic areas
where injection drug use is the main form of
transmission.6
Hepatitis C virus (HCV) was first identified in 1989
as a member of flaviviridae. Now, an estimate of 170
millions people worldwide are infected with hepatitis C
virus. Nowadays, the majority of patients with acute
HCV infection are intravenous drug users and the risk
of vertical transmission from HCV infected mothers to
their children is only 1% to 5%. Recent studies on acute
infection demonstrated that sexual contact with an HCV
positive partner was the only risk factor to be identified
in 20% to 30% of patients. Other potential exposure
(occupational, hemodialysis, household) account for about
10% of new infextions.7 Although it is widely accepted
that hepatitis C virus infection is a major cause of
an end-state liver disease and hepatocelluler carcinoma,
the natural history and hence the prognosis of the
infection are still controversial.
Since HCV is a non-cytopathic virus in most
circumstances, the immune response almost certainly
plays a central role, not only for the control of
the infection, but also for the pathogenesis of liver
disease and the progression of acute HCV infections to
chronic cases, occur in approximately 75% to 85%8 and
it always implies the presence of some degree of liver
damage in chronic viral hepatitis.9
PATHOGENESIS OF LIVER DAMAGE
Virus-specific CD8 T cells represent the main
effector cells against a viral infection, where as the
antiviral cytokines has a major role in the control of viral
replication (non-cytolytic inhibition).
The appearance of CD8+ human leukocyte antigen-
restricted cytotoxic T cells is important in the
pathogenesis of liver cells damage and that cell necrosis
in several viral infections in humans, can be mediated by
cytotoxic T lymphocytes (CTLS) that recognize viral
antigens on the surface of infected cells in the context
of HLA class.10
T lymphocytes can be cytotoxic and destroy infected
cells by inducing apoptosis through the release of perforin,
granzyme and secrete cytokines such as TNF-alpha and
interferon gamma.7 Three distinct mechanisms, namely
Fas, TNF alpha and/or perforin-based cell lysis have been
implicated in hepatocyt death during inflammatory liver
disease.11 Fas-mediated death is a rapid process, requires
neither  RNA  nor  protein synthesis. Expression of Fas
(CD 95), a mediator of apoptosis is required the induce
the death of the hepatocyts.
TNF-mediated apoptosis can be induced by
membrane–bound and soluble TNF alpha, whereas
the perforin–mediated mechanism may contribute to
the lysis of antigen presenting, Fas and TNF alpha
resistant cells.11
The presence of a CTL response that unable to
control viral infection, could then cause chronic
recruitment of inflammatory cells that will sustain
necro–inflammatory activity, promoting the long-term
complication of  viral  infection such as fibrosis, cirrhosis
and hepatocellular carcinoma.5 How do hepatotropic
viruses cause chronic infection in the liver ?
MECHANISMS OF LIVER PERSISTENCE
Chronic infection with persisting hepatitis viruses B
or C (HBV or HCV) reflex an initially ineffective
immune response to hepatocyt that express viral
antigens, resulting in an unstable balance between
tolerance and immunity to infected hepatocyt, with
multiple host and viral determinants in play.
To cause persistent infection in the liver, a virus must
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avoid host defences and the hepatotropic viruses have
developed elaborate strategies to achieve this.4
The innate immune system is the first line of defence
against pathogens and the most important innate
antiviral defence system is the type I interferons. These
interferons are rapidly produced by virally infected cells
and once released, they bind to cell surface receptors
and induce the production of a large number of proteins
that inhibit viral replication.
The functions of some of the proteins that are
induced by type I interferons are well characterized, but
no function has been identified for many of them. Some
of the interferon-inducible proteins are produced in an
inactive form and are activated by viral products. For
example, type I interferon induce the production of
a protein kinase known as PKR. In the presence of
a replicating RNA virus, this protein is activated by double
stranded RNA and the activated kinase, inhibits cellular
protein production, thereby leading to suppression of  viral
replication, whereas other interferon-inducible proteins
inhibit the replication of other viruses.4
It is assumed that many hundreds or so
interferon-induced proteins identified to date, inhibits the
replication of specific viruses, although not all of the
targets have been identified.
In addition to activating an antiviral state in cells
exposed to viruses, the type I interferon’s have
immunomodulatory effects. They facilitate immune
recognition of virally infected cells by increasing the cell
surface expression of human leucocyte antigen (HLA)
class I antigen. This presentation of viral antigens to T
cells is enhanced by type I interferon, which up-regulate
HLA class I antigens.
Viruses that lead to prolonged infection must have
developed mechanisms to overcome the effect of these
interferon and many viruses encode proteins that inhibit
interferon system in some way.4
In the case hepatitis B virus; two proteins are
involved in this inhibition:
1. The core protein which inhibits the production of
interferon
2. The polymerase protein which inhibits the effect of
interferon
In the case of hepatitis C virus, the NS5A and E2
proteins reduce the effect of interferon, by inhibiting the
viral kinase, PKR.4 The NS5A region has been
associated with sensitivity to interferon in genotype 1b
isolate in Japan.12
So, persistent viral infection is associated with
avoidance of both arms of the immune system and the
exact mechanisms of persistent viral infection are not
completely understood, possibly through:
1. Mutation of viral proteins
2. By preventing activation of the immune system.4
3. Inhibit the generation of an appropriate immune
response, e.g. The infection of dendritic cells as one
mechanism which may be used by hepatitis C virus.
In vertical transmission, hepatitis B virus produces a
small protein (HBeAg), which crosses the placenta and
induces tolerance to itself and related hepatitis B
proteins. Since the immune system has come to contact
with the protein in early life, the immune system then
believes the protein to be self and is therefore unable to
mount an effective immune system.4
CONCLUSIONS
1. Chronic viral hepatitis commonly cause by three
hepatotropic viruses, hepatitis B virus (HBV),
hepatitis delta virus (HDV), hepatitis C virus (HCV).
2. Virus specific CD8 T cells represent the major
effector cells againt a viral infection, where as
the antiviral cytokines has major role in the control
of viral replication (non-cytolytic inhibition).
3. Persistent viral infection is associated with
avoidance of both arms of the immune system by
the hepatotropic viruses, either by producing proteins
that inhibit the action of interferon, by mutation of
viral proteins or inhibit the generation of
an appropriate immune response, so that
the antibody or T cell can no longer recognize
the viral protein and hence the virus can evade
the antiviral defence of the body.
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